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used. Cartilage degradation was monitored by measuring the
conditioned medium in 4 independent assays (1) 342-G2 assay,
composed of the capturing antibody AF-28 against the 342FFGVG
neo-epitope generated by MMP-cleavage and the monoclonal
antibody F-78 binding to both the Globular 1 (G1) and Globu-
lar 2 (G2) domain of aggrecan; (2) 374-G2 assay, made up by
the capturing antibody BC-3 against the 374ARGSVI neo-epitope
created by ADAMTs cleavage and F-78; (3) MMP mediated colla-
gen type II degradation (CTX-II) quantified by ELISA; (4) release
of total glycosaminoglycans (GAGs). Furthermore, immunohisto-
chemistry was performed with the monoclonal antibodies AF-28
and BC-3 on OA cartilage to localize the epitopes.
Results: OSM/TNFα caused a significant release of aggre-
canase mediated 374-G2 containing molecules in the early (day
4-9), mid (day 10-15) and late phase (day 16-21) and GAGs in
the early and mid phase compared to non-stimulated explants
(1000 fold increase of 374-G2 at day 14). On the other hand,
stimulation with IL-1α resulted in a release of aggrecanase me-
diated 374-G2 antigens and GAGs in the mid and late phase
when compared to non-stimulated explants (50 fold increase of
374-G2 at day 14). No remarkable release of MMP mediated
CTX-II or 342-G2 analytes were detected with OSM/TNFα or IL-
1α throughout the whole period. Immunohistochemistry showed
an intense staining with BC-3 in the calcified cartilage zone and
in the articular surface, where erosion had occurred.
Conclusions: In the present study, we have shown that stim-
ulation of ex vivo human explant cultures with OSM/TNFα or
IL-1α results in release of aggrecanase mediated 374-G2 an-
alytes, but not MMP mediated 342-G2 molecules. By careful
assessment of biochemical markers, these provide information
on which proteases are activated, when stimulating explants with
pro-inflammatory cytokines. We suggest that these assays are
valuable diagnostic tools for assessing the turnover of aggre-
can in human arthritis, which may aid in understanding disease
mechanisms leading to pathologies such as OA.
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Purpose: Osteoarthritis (OA) is usually used as a control for
rheumatoid arthritis (RA) when measuring innate and specific re-
ceptor levels. However, there is evidence that there is a systemic
inflammatory component to OA as well. In the current study, we
examined CD14+ peripheral blood monocytes from OA patients
for the expression of Toll-like receptors (TLR), TLR2 and TLR4,
and co-stimulatory molecules, CD80 and CD86, in order to de-
termine whether the cells from OA patients have increased levels
compared with normals. Monocytes from RA patients were also
compared.
Methods: Blood was collected 45 patients with OA, 45 patients
with RA, and 25 normals. TLR2 and TLR4 expression on CD14+
peripheral blood mononuclear cells (PBMCs) were measured by
flow cytometry using anti-CD14, anti-TLR2 and anti-TLR4 mono-
clonal antibodies. CD80 and CD86 expression on CD14+PBMCs
were also measured by flow cytometry using anti-CD14, anti-
CD80 and anti-CD86 monoclonal antibodies. Appropriate isotype
controls were used. Results are expressed as a ratio to control.
Results: Preliminary data suggest TLR2 expression (expressed
as a ratio to control) was significantly increased for OA patients
(p<0.05) and RA patients (p<0.05), compared with normals. For
OA monocytes, TLR4 expression (expressed as a ratio to control)
was no different to normals, whereas expression was decreased
on cells from RA patients (p<0.05). CD14highCD16+ monocytes
showed the greatest expression of TLR2 on both OA and RA
monocytes. The co-stimulatory molecules CD80 and CD86 were
not increased on OA monocytes, whereas CD86 was increased
on RA monocytes.
Conclusions: OA monocytes show some differences from nor-
mal monocytes, at least in TLR2 expression, suggesting perhaps
that aspects of the innate immune system may be involved in OA
pathogenesis.
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Purpose: To evaluate the sensitivity of a panel of biomarkers for
type II collagen turnover, alone or in combination, to differentiate
patients with radiographic and symptomatic osteoarthritis (OA)
from healthy controls that could be used to help monitor OA
disease progression and therapeutic intervention.
Methods: Levels of the urinary type II collagen degradation
biomarkers uCTX-II and uTIINE, and the blood type II collagen
synthesis biomarkers plNPII, sCPII and sPIIANP were measured
in 177 subjects aged > 40 years (mean = 57). Eighty-four
patients had symptomatic OA in at least one knee. The diagnosis
of symptomatic OA (SOA) was based on a combination of pain
or stiffness on most days of a month during the past year and
the presence of radiographic OA as defined by Kellgren and
Lawrence grades (KLG) 2 and 3. Ninety-three age- and sex-
matched healthy controls had no symptoms and a KLG = 0.
ELISA assays were used to measure uCTX-II, sPIIANP (Synarc,
France) and sCPII (IBEX, Canada). uTIINE was measured by
LC/MS/MS and plNPII was measured by a recently developed
competitive ELISA assay in-house. Statistical analyses were
performed on Log-transformed data.
Results: The mean (SD) levels of uCTXII, uTIINE, plNPII, sCPII
and sPIIANP, were 203.39 (119.8) ng/mmol Creat, 76.95 (48.89)
ng/mmol Creat, 3.48 (3.65) ng/mL, 402.43 (126.83) ng/mL and
902.97 (669.55) ng/mL, respectively. The uCTXII and uTIINE
levels were significantly larger in OA patients compared to control
subjects (P-value <0.001). In contrast, the plNPII levels were
significantly smaller in OA patients compared to control subjects
(P-value = 0.04). Both sCPII and sPIIANP levels were similar
in both groups (P-value = 0.52 and 0.27, respectively). Levels
of both degradation markers uCTX-II and uTIINE were well
correlated (R = 0.64, p < 0.0001). Among the synthesis markers,
